Effect of therapy with latamoxef (moxalactam) on carriage of Clostridium difficile.
Twenty-seven patients receiving latamoxef (moxalactam) as a single antimicrobial agent were studied prospectively for Clostridium difficile carriage and development of diarrhoea or colitis. Stools were available prior to therapy from only seven patients, one of whom (14.3%) was an asymptomatic carrier. None of twelve patients studied during therapy were carriers. Seven of 27 patients (25.9%) were colonized with Cl. difficile after completion of latamoxef therapy, and three patients had cytotoxin positive stools. Two patients with cytotoxin grew Cl difficile from stools and one patient was culture negative. Only one patient, who had both culture and cytotoxin positive stools, had profuse diarrhoea. Cl. difficile clinical isolates were only moderately susceptible to latamoxef in vitro. Hamsters given moxalactam developed caecitis. Patients receiving latamoxef, or third generation cephalosporins, may be at increased risk of development of Cl. difficile associated diarrhoea and should be followed closely for this complication, especially after therapy has been discontinued.
D000818:Animals; D002353:Carrier State / Q000188:drug therapy*; D003015:Clostridium Infections / Q000188:drug therapy*; D003092:Colitis / Q000139:chemically induced; D006224:Cricetinae; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008647:Mesocricetus; D008826:Microbial Sensitivity Tests; D009070:Moxalactam / Q000009:adverse effects / Q000627:therapeutic use*
D009070:Moxalactam